{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:13:51Z","timestamp":1770905631495,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Kawasaki disease is an acute multisystem childhood vasculitis with a predilection for the coronary arteries. The role of corticosteroids and acetyl salicylic acid (ASA) in the treatment of acute Kawasaki disease are matters of ongoing debate and changing attitudes from one extreme to the other. Recent work has provided new evidence to guide our thinking about these two therapeutic agents, which will be the focus of this review.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Corticosteroids are effective and well tolerated in Kawasaki disease, both as initial adjunctive treatment in those at high-risk for poor outcome, and as rescue therapy after failed intravenous immunoglobulin (IVIG).<\/jats:p>\n            <jats:p>Higher doses of ASA (&gt; 30\u200amg\/kg\/day) in the acute phase of Kawasaki disease, have no clear benefit over antiplatelet doses in improving coronary outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Corticosteroids should be used in patients at high-risk for poor coronary outcome, and in patients who fail IVIG. The absence of widely applicable and validated risk-scoring systems in Kawasaki disease outside of Japan remains a limiting factor to identify high-risk children. Current evidence does not demonstrate any advantage of high-dose over low-dose ASA in the acute phase of Kawasaki disease, in preventing coronary artery aneurysms.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000425","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T15:20:37Z","timestamp":1498663237000},"page":"547-552","source":"Crossref","is-referenced-by-count":12,"title":["Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease"],"prefix":"10.1097","volume":"29","author":[{"given":"Anita","family":"Dhanrajani","sequence":"first","affiliation":[{"name":"Hospital for Sick Children"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rae S.M.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Hak-Ming and Deborah Chiu Chair in Paediatric Translational Research, Professor of Paediatrics, Immunology and Medical Science, University of Toronto, Senior Scientist and Rheumatologist, The Hospital for Sick Children, Toronto, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1442-200X.2010.03092.x","article-title":"Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006","volume":"52","author":"Lin","year":"2010","journal-title":"Pediatr Int"},{"key":"R2-20230829","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association","volume":"135","author":"McCrindle","year":"2017","journal-title":"Circulation"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/ped.12317","article-title":"Guidelines for medical treatment of acute Kawasaki disease: Report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version)","volume":"56","year":"2014","journal-title":"Pediatrics Intl"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1542\/peds.63.2.175","article-title":"Kawasaki disease: effect of treatment on coronary artery involvement","volume":"63","author":"Kato","year":"1979","journal-title":"Pediatrics"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1253\/jcj.46.1239","article-title":"A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease","volume":"46","author":"Kijima","year":"1982","journal-title":"Jpn Circ J"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0022-3476(05)80972-2","article-title":"Gamma globulin re-treatment in Kawasaki disease","volume":"123","author":"Sundel","year":"1993","journal-title":"J Pediatr"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0022-3476(99)70169-1","article-title":"Corticosteroids in the treatment of the acute phase of Kawasaki disease","volume":"135","author":"Shinohara","year":"1999","journal-title":"J Pediatr"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2010.08.070","article-title":"Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression","volume":"154","author":"Millar","year":"2012","journal-title":"Int J Cardiol"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1067\/mpd.2003.191","article-title":"Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial","volume":"142","author":"Sundel","year":"2003","journal-title":"J Pediatr"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jpeds.2006.05.025","article-title":"A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome","volume":"149","author":"Inoue","year":"2006","journal-title":"J Pediatr"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJMoa061235","article-title":"Pediatric Heart Network Investigators. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease","volume":"356","author":"Newburger","year":"2007","journal-title":"N Engl J Med"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","article-title":"RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial","volume":"379","author":"Kobayashi","year":"2012","journal-title":"Lancet"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/heartjnl-2012-302126","article-title":"Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis","volume":"99","author":"Chen","year":"2013","journal-title":"Heart"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/ped.13190","article-title":"Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease","volume":"59","author":"Kimura","year":"2017","journal-title":"Pediatr Int"},{"key":"R15-20230829","first-page":"CD011188","article-title":"Corticosteroids for the treatment of Kawasaki disease in children","volume":"1","author":"Wardle","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/jamapediatrics.2016.2055","article-title":"Coronary artery complication in Kawasaki disease and the importance of early intervention: a systematic review and meta-analysis","volume":"170","author":"Chen","year":"2016","journal-title":"JAMA Pediatr"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jamapediatrics.2016.2307","article-title":"Clarifying the role of corticosteroids in Kawasaki disease","volume":"170","author":"Sundel","year":"2016","journal-title":"JAMA Pediatr"},{"key":"R18-20230829","first-page":"401","article-title":"Efficacy and risks of aspirin in the treatment of the Kawasaki disease","volume":"250","author":"Kusakawa","year":"1987","journal-title":"Prog Clin Biol Res"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0022-3476(88)80194-X","article-title":"Determinants of low serum concentrations of salicylates in patients with Kawasaki disease","volume":"112","author":"Koren","year":"1988","journal-title":"J Pediatr"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1542\/peds.96.6.1057","article-title":"The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment","volume":"96","author":"Durongpisitkul","year":"1995","journal-title":"Pediatrics"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1442-200X.1991.tb02611.x","article-title":"Intravenous gamma-globulin for Kawasaki disease","volume":"33","author":"Furusho","year":"1991","journal-title":"Acta Paediatrica Japonica"},{"key":"R22-20230829","first-page":"888","article-title":"Prevalence of coronary artery abnormalities in disease is highly dependent on gamma dose but independent of salicylate dose","volume":"13","author":"Masaru","year":"1997","journal-title":"J Pediatr"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1542\/peds.2004-1037","article-title":"Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited","volume":"114","author":"Hsieh","year":"2004","journal-title":"Pediatrics"},{"key":"R24-20230829","first-page":"CD004175","article-title":"Salicylate for the treatment of Kawasaki disease in children","volume":"4","author":"Baumer","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/archdischild-2012-302841","article-title":"Management of Kawasaki disease","volume":"99","author":"Eleftheriou","year":"2014","journal-title":"Arch Dis Child"},{"key":"R26-20230829","first-page":"209","article-title":"High-dose aspirin for Kawasaki disease: outdated myth or effective aid?","volume":"103","author":"Amarilyo","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jpeds.2016.12.019","article-title":"Medium- or higher-dose acetylsalicylic acid for acute Kawasaki disease and patient outcomes","volume":"184","author":"Kim","year":"2017","journal-title":"J Pediatr"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/art.24660","article-title":"Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease","volume":"60","author":"Lau","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201709000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:47:15Z","timestamp":1693291635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201709000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000425","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}